CG Oncology, Inc. (CGON) Stock Statistics & Valuation Metrics

CG Oncology, Inc. has a market cap or net worth of $1.65B. The enterprise value is $1.44B.

CG Oncology, Inc. has 76,221,855 shares outstanding. The number of shares has decreased by -2.65% in one year.

CG Oncology, Inc.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -15.63%.

The current PE Ratio of CG Oncology, Inc. is -20.36. CG Oncology, Inc.’s PEG ratio is 0.22.

In the last 12 months, CG Oncology, Inc. had revenue of 0.00 and earned -88.04M in profits. Earnings per share was -1.41.

In the last 12 months, operating cash flow was -74.11M and capital expenditures -25.00K, giving a free cash flow of -74.14M billion.

CG Oncology, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

CG Oncology, Inc. upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

CG Oncology, Inc. as a current ratio of 35.30, with Debt / Equity ratio of 0.06%

In the past 12 months, CG Oncology, Inc. has paid -88.04M in taxes.

CG Oncology, Inc. EV to EBITDA ratio is -13.39, with an EV/FCF ratio of -19.45.

CG Oncology, Inc. has $540.71M in cash and marketable securities with $16.30M in debt, giving a net cash position of -$540.41M billion.

Gross margin is 97.81%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for CG Oncology, Inc. is $60.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy